An update on the pharmacological management and prevention of cerebral edema: current therapeutic strategies

References

• Liebeskind DS, Jüttler E, Shapovalov Y, et al. Cerebral edema associated with large hemispheric infarction. Stroke. 2019 Sep;50(9):2619–2625.
   PubMed Web of Science ®Google Scholar
• Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology. 2019 Feb;145(Pt B):230–246.
   PubMed Web of Science ®Google Scholar
• Esquenazi Y, Lo VP, Lee K. Critical care management of cerebral edema in brain tumors. J Intensive Care Med. 2017 Jan;32(1):15–24.
   PubMed Web of Science ®Google Scholar
• Zheng H, Chen C, Zhang J, et al. Mechanism and therapy of brain edema after intracerebral hemorrhage. Cerebrovasc Dis. 2016;42(3–4):155–169.
   PubMed Web of Science ®Google Scholar
• Suarez JI. Diagnosis and management of subarachnoid hemorrhage. Continuum (Minneap Minn). 2015 Oct;21(5Neurocritical Care):1263–1287.
   PubMedGoogle Scholar
• Wijdicks EF, Longo DL. Hepatic encephalopathy. N Engl J Med. 2016 Oct 27;375(17):1660–1670.
   PubMed Web of Science ®Google Scholar
• Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010 Jun;23(3):293–299.
   PubMed Web of Science ®Google Scholar
• Kochanek KD, Xu J, Murphy SL, et al. Deaths: final data for 2009. Natl Vital Stat Rep. 2011 Dec 29;60(3):1–116.
   PubMedGoogle Scholar
• Hanid MA, Davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut. 1980 Oct;21(10):866–869.
   PubMed Web of Science ®Google Scholar
• Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007 Mar;6(3):258–268.
   PubMed Web of Science ®Google Scholar
• Unterberg AW, Stover J, Kress B, et al. Edema and brain trauma. Neuroscience. 2004;129(4):1021–1029. .
   PubMed Web of Science ®Google Scholar
• Norenberg MD. Astrocyte responses to CNS injury. J Neuropathol Exp Neurol. 1994 May;53(3):213–220.
   PubMed Web of Science ®Google Scholar
• Su G, Kintner DB, Flagella M, et al. Astrocytes from Na(+)-K(+)-Cl(-) cotransporter-null mice exhibit absence of swelling and decrease in EAA release. Am J Physiol Cell Physiol. 2002 May;282(5):C1147–60.
   PubMed Web of Science ®Google Scholar
• Su G, Kintner DB, Sun D. Contribution of Na(+)-K(+)-Cl(-) cotransporter to high-[K(+)](o)- induced swelling and EAA release in astrocytes. Am J Physiol Cell Physiol. 2002 May;282(5):C1136–46.
   PubMed Web of Science ®Google Scholar
• Beck J, Lenart B, Kintner DB, et al. Na-K-Cl cotransporter contributes to glutamate-mediated excitotoxicity. J Neurosci. 2003 Jun 15;23(12):5061–5068.
   PubMed Web of Science ®Google Scholar
• Chen M, Dong Y, Simard JM. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci. 2003 Sep 17;23(24):8568–8577.
   PubMed Web of Science ®Google Scholar
• Jakubovicz DE, Klip A. Lactic acid-induced swelling in C6 glial cells via Na+/H+ exchange. Brain Res. 1989 Apr 24;485(2):215–224.
   PubMed Web of Science ®Google Scholar
• Walcott BP, Kahle KT, Simard JM. Novel treatment targets for cerebral edema. Neurotherapeutics. 2012 Jan;9(1):65–72.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. J Cereb Blood Flow Metab. 2016 Mar;36(3):513–538.
   PubMed Web of Science ®Google Scholar
• Cook AM, Morgan Jones G, Hawryluk GWJ, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocrit Care. 2020 Jun;32(3):647–666.
   PubMed Web of Science ®Google Scholar
• Koenig MA. Cerebral edema and elevated intracranial pressure. Continuum (Minneap Minn). 2018 Dec;24(6):1588–1602.
   PubMedGoogle Scholar
• Riha HM, Erdman MJ, Vandigo JE, et al. Impact of moderate hyperchloremia on clinical outcomes in intracerebral hemorrhage patients treated with continuous infusion hypertonic saline: a pilot study. Crit Care Med. 2017 Sep;45(9):e947–e953.
   PubMed Web of Science ®Google Scholar
• Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore). 1990 May;69(3):153–159.
   PubMed Web of Science ®Google Scholar
• Gondim Fde A, Aiyagari V, Shackleford A, et al. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg. 2005 Sep;103(3):444–447.
   PubMed Web of Science ®Google Scholar
• García-Morales EJ, Cariappa R, Parvin CA, et al. Osmole gap in neurologic-neurosurgical intensive care unit: its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med. 2004 Apr;32(4):986–991.
   PubMed Web of Science ®Google Scholar
• Rossini Z, Nicolosi F, Kolias AG, et al. The History of Decompressive Craniectomy in Traumatic Brain Injury. Front Neurol. 2019;10:458
   PubMed Web of Science ®Google Scholar
• Cushing HI. Subtemporal decompressive operations for the intracranial complications associated with bursting fractures of the skull. Ann Surg. 1908 May;47(5):641–644.1.
   PubMedGoogle Scholar
• Badri S, Chen J, Barber J, et al. Mortality and long-term functional outcome associated with intracranial pressure after traumatic brain injury. Intensive Care Med. 2012 Nov;38(11):1800–1809.
   PubMed Web of Science ®Google Scholar
• Balestreri M, Czosnyka M, Hutchinson P, et al. Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury. Neurocrit Care. 2006;4(1):8–13.
   PubMed Web of Science ®Google Scholar
• Cooper DJ, Rosenfeld JV, Murray L, et al. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med. 2011 Apr 21;364(16):1493–1502.
   PubMed Web of Science ®Google Scholar
• Hutchinson PJ, Kolias AG, Timofeev IS, et al. Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med. 2016 Sep 22;375(12):1119–1130.
   PubMed Web of Science ®Google Scholar
• Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, Fourth Edition. Neurosurgery. 2017 Jan 1;80(1):6–15.
   PubMed Web of Science ®Google Scholar
• Hutchinson PJ, Kolias AG, Tajsic T, et al. Consensus statement from the international consensus meeting on the role of decompressive craniectomy in the management of traumatic brain injury: consensus statement. Acta Neurochir (Wien). 2019 Jul;161(7):1261–1274.
   PubMed Web of Science ®Google Scholar
• Hacke W, Schwab S, Horn M, et al. ‘Malignant’ middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996 Apr;53(4):309–315.
   PubMed Web of Science ®Google Scholar
• Berrouschot J, Sterker M, Bettin S, et al. Mortality of space-occupying (‘malignant’) middle cerebral artery infarction under conservative intensive care. Intensive Care Med. 1998 Jun;24(6):620–623.
   PubMed Web of Science ®Google Scholar
• Hofmeijer J, van der Worp HB, Kappelle LJ. Treatment of space-occupying cerebral infarction. Crit Care Med. 2003 Feb;31(2):617–625.
   PubMed Web of Science ®Google Scholar
• Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke. 2007 Sep;38(9):2506–2517.
   PubMed Web of Science ®Google Scholar
• Jüttler E, Schwab S, Schmiedek P, et al. Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke. 2007 Sep;38(9):2518–2525.
   PubMed Web of Science ®Google Scholar
• Jüttler E, Bösel J, Amiri H, et al. DESTINY II: dEcompressive Surgery for the Treatment of malignant INfarction of the middle cerebral arterY II. Int J Stroke. 2011 Feb;6(1):79–86.
   PubMed Web of Science ®Google Scholar
• Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. 2009 Apr;8(4):326–333.
   PubMed Web of Science ®Google Scholar
• Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007 Mar;6(3):215–222.
   PubMed Web of Science ®Google Scholar
• Park JH, Saier MH Jr. Phylogenetic, structural and functional characteristics of the Na-K-Cl cotransporter family. J Membr Biol. 1996 Feb;149(3):161–168.
   PubMed Web of Science ®Google Scholar
• Kahle KT, Simard JM, Staley KJ, et al. Molecular mechanisms of ischemic cerebral edema: role of electroneutral ion transport. Physiology (Bethesda). 2009 Aug;24:257–265.
   PubMed Web of Science ®Google Scholar
• Liang D, Bhatta S, Gerzanich V, et al. Cytotoxic edema: mechanisms of pathological cell swelling. Neurosurg Focus. 2007 May 15;22(5):E2.
   PubMedGoogle Scholar
• Jayakumar AR, Norenberg MD. The Na-K-Cl Co-transporter in astrocyte swelling. Metab Brain Dis. 2010 Mar;25(1):31–38.
   PubMed Web of Science ®Google Scholar
• Kahle KT, Staley KJ, Nahed BV, et al. Roles of the cation-chloride cotransporters in neurological disease. Nat Clin Pract Neurol. 2008 Sep;4(9):490–503.
   PubMedGoogle Scholar
• Zhang J, Karimy JK, Delpire E, et al. Pharmacological targeting of SPAK kinase in disorders of impaired epithelial transport. Expert Opin Ther Targets. 2017 Aug;21(8):795–804.
   PubMed Web of Science ®Google Scholar
• Chen H, Sun D. The role of Na-K-Cl co-transporter in cerebral ischemia. Neurol Res. 2005 Apr;27(3):280–286.
   PubMed Web of Science ®Google Scholar
• Lu KT, Cheng NC, Wu CY, et al. NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade. Crit Care Med. 2008 Mar;36(3):917–922.
   PubMed Web of Science ®Google Scholar
• Yan Y, Dempsey RJ, Flemmer A, et al. Inhibition of Na(+)-K(+)-Cl(-) cotransporter during focal cerebral ischemia decreases edema and neuronal damage. Brain Res. 2003 Jan 24;961(1):22–31.
   PubMed Web of Science ®Google Scholar
• Chen H, Luo J, Kintner DB, et al. Na(+)-dependent chloride transporter (NKCC1)-null mice exhibit less gray and white matter damage after focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jan;25(1):54–66.
   PubMed Web of Science ®Google Scholar
• Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006 Apr;12(4):433–440.
   PubMed Web of Science ®Google Scholar
• Simard JM, Kahle KT, Gerzanich V. Molecular mechanisms of microvascular failure in central nervous system injury–synergistic roles of NKCC1 and SUR1/TRPM4. J Neurosurg. 2010 Sep;113(3):622–629.
   PubMed Web of Science ®Google Scholar
• Conti L, Palma E, Roseti C, et al. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex. Epilepsia. 2011 Sep;52(9):1635–1644.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Valdes V, Norenberg MD. The Na-K-Cl cotransporter in the brain edema of acute liver failure. J Hepatol. 2011 Feb;54(2):272–278.
   PubMed Web of Science ®Google Scholar
• Zhao H, Nepomuceno R, Gao X, et al. Deletion of the WNK3-SPAK kinase complex in mice improves radiographic and clinical outcomes in malignant cerebral edema after ischemic stroke. J Cereb Blood Flow Metab. 2017 Feb;37(2):550–563.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Panickar KS, Curtis KM, et al. Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury. J Neurochem. 2011 May;117(3):437–448.
   PubMed Web of Science ®Google Scholar
• Wang G, Huang H, He Y, et al. Bumetanide protects focal cerebral ischemia-reperfusion injury in rat. Int J Clin Exp Pathol. 2014;7(4):1487–1494.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bhuiyan MIH, Zhang T,et al. Modulation of brain cation-Cl(-) cotransport via the SPAK kinase inhibitor ZT-1a. Nat Commun. 2020 Jan 7;11(1):78.
   PubMed Web of Science ®Google Scholar
• Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol. 2015 May;14(5):469–477.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013 Jan;54(1):e9–12.
   PubMed Web of Science ®Google Scholar
• Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012 Dec 11;2(12):e202.
   PubMed Web of Science ®Google Scholar
• Lemonnier E, Lazartigues A, Ben-Ari Y. Treating schizophrenia with the diuretic bumetanide: a case report. Clin Neuropharmacol. 2016 Mar-Apr;39(2):115–117.
   PubMed Web of Science ®Google Scholar
• Rahmanzadeh R, Eftekhari S, Shahbazi A, et al. Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial. Schizophr Res. 2017 Jun;184:145–146.
   PubMed Web of Science ®Google Scholar
• Wilkinson CM, Fedor BA, Aziz JR, et al. Failure of bumetanide to improve outcome after intracerebral hemorrhage in rat. PLoS One. 2019;14(1):e0210660.
   PubMed Web of Science ®Google Scholar
• Luo ZW, Ovcjak A, Wong R, et al. Drug development in targeting ion channels for brain edema. Acta Pharmacol Sin. 2020 Oct;41(10):1272–1288.
   PubMed Web of Science ®Google Scholar
• Huang H, Bhuiyan MIH, Jiang T, et al. A novel Na(+)-K(+)-Cl(-) Cotransporter 1 Inhibitor STS66* reduces brain damage in mice after ischemic stroke. Stroke. 2019 Apr;50(4):1021–1025.
   PubMed Web of Science ®Google Scholar
• Badaut J, Lasbennes F, Magistretti PJ, et al. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab. 2002 Apr;22(4):367–378.
   PubMed Web of Science ®Google Scholar
• Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009 Feb 6;158(3):983–994.
   PubMed Web of Science ®Google Scholar
• Rosell A, Ortega-Aznar A, Alvarez-Sabín J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 2006 Jun;37(6):1399–1406.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998 Oct;29(10):2189–2195.
   PubMed Web of Science ®Google Scholar
• Fallier-Becker P, Sperveslage J, Wolburg H, et al. The impact of agrin on the formation of orthogonal arrays of particles in cultured astrocytes from wild-type and agrin-null mice. Brain Res. 2011 Jan;7(1367):2–12.
   Web of Science ®Google Scholar
• Wolburg H, Noell S, Wolburg-Buchholz K, et al. Agrin, aquaporin-4, and astrocyte polarity as an important feature of the blood-brain barrier. Neuroscientist. 2009 Apr;15(2):180–193.
   PubMed Web of Science ®Google Scholar
• Wolburg-Buchholz K, Mack AF, Steiner E, et al. Loss of astrocyte polarity marks blood-brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol. 2009 Aug;118(2):219–233.
   PubMed Web of Science ®Google Scholar
• Fukuda AM, Badaut J. Aquaporin 4: a player in cerebral edema and neuroinflammation. J Neuroinflammation. 2012 Dec 27;9:279.
   PubMed Web of Science ®Google Scholar
• Hu H, Yao HT, Zhang WP, et al. Increased expression of aquaporin-4 in human traumatic brain injury and brain tumors. J Zhejiang Univ Sci B. 2005 Jan;6(1):33–37.
   PubMedGoogle Scholar
• Qing WG, Dong YQ, Ping TQ, et al. Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. J Neurosurg. 2009 Mar;110(3):462–468.
   PubMed Web of Science ®Google Scholar
• Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. Int J Mol Sci. 2015 Apr 30;16(5):9949–9975.
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. Faseb J. 2004 Aug;18(11):1291–1293.
   PubMed Web of Science ®Google Scholar
• Tang Y, Wu P, Su J, et al. Effects of Aquaporin-4 on edema formation following intracerebral hemorrhage. Exp Neurol. 2010 Jun;223(2):485–495.
   PubMed Web of Science ®Google Scholar
• Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000 Feb;6(2):159–163.
   PubMed Web of Science ®Google Scholar
• Rama Rao KV, Verkman AS, Curtis KM, et al. Aquaporin-4 deletion in mice reduces encephalopathy and brain edema in experimental acute liver failure. Neurobiol Dis. 2014 Mar;63:222–228.
   PubMed Web of Science ®Google Scholar
• Igarashi H, Huber VJ, Tsujita M, et al. Pretreatment with a novel aquaporin 4 inhibitor, TGN-020, significantly reduces ischemic cerebral edema. Neurol Sci. 2011 Feb;32(1):113–116.
   PubMed Web of Science ®Google Scholar
• Farr GW, Hall CH, Farr SM, et al. Functionalized phenylbenzamides inhibit aquaporin-4 reducing cerebral edema and improving outcome in two models of CNS injury. Neuroscience. 2019 Apr 15;404:484–498.
   PubMed Web of Science ®Google Scholar
• Nakano T, Nishigami C, Irie K, et al. Goreisan prevents brain edema after cerebral ischemic stroke by inhibiting aquaporin 4 upregulation in mice. J Stroke Cerebrovasc Dis. 2018 Mar;27(3):758–763.
   PubMed Web of Science ®Google Scholar
• Zhang M, Cui Z, Cui H, et al. Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice. BMC Neurosci. 2016;17(1):60.
   PubMed Web of Science ®Google Scholar
• Wallisch JS, Janesko-Feldman K, Alexander H, et al. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511–517.
   PubMed Web of Science ®Google Scholar
• Seo JH, Guo S, Lok J, et al. Neurovascular matrix metalloproteinases and the blood-brain barrier. Curr Pharm Des. 2012;18(25):3645–3648.
   PubMed Web of Science ®Google Scholar
• Planas AM, Solé S, Justicia C. Expression and activation of matrix metalloproteinase-2 and −9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis. 2001 Oct;8(5):834–846.
   PubMed Web of Science ®Google Scholar
• Jia F, Pan YH, Mao Q, et al. Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. J Neurotrauma. 2010 Jun;27(6):1059–1068.
   PubMed Web of Science ®Google Scholar
• Liu W, Hendren J, Qin X-J, et al. Normobaric hyperoxia attenuates early blood–brain barrier disruption by inhibiting MMP-9-mediated occludin degradation in focal cerebral ischemia. J Neurochem. 2009 Feb 01;108(3):811–820.
   PubMed Web of Science ®Google Scholar
• Dong H, Fan Y-H, Zhang W, et al. Repeated electroacupuncture preconditioning attenuates matrix metalloproteinase-9 expression and activity after focal cerebral ischemia in rats. Neurol Res. 2009 Oct 01;31(8):853–858.
   PubMed Web of Science ®Google Scholar
• Li DD, Song JN, Huang H, et al. The roles of MMP-9/TIMP-1 in cerebral edema following experimental acute cerebral infarction in rats. Neurosci Lett. 2013 Aug 29;550:168–172.
   PubMed Web of Science ®Google Scholar
• Shigemori Y, Katayama Y, Mori T, et al. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir Suppl. 2006;96:130–133.
   PubMedGoogle Scholar
• Feiler S, Plesnila N, Thal SC, et al. Contribution of matrix metalloproteinase-9 to cerebral edema and functional outcome following experimental subarachnoid hemorrhage. Cerebrovasc Dis. 2011;32(3):289–295.
   PubMed Web of Science ®Google Scholar
• Chaturvedi M, Kaczmarek L. Mmp-9 inhibition: a therapeutic strategy in ischemic stroke. Mol Neurobiol. 2014 Feb;49(1):563–573.
   PubMed Web of Science ®Google Scholar
• Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain. 2005 Jul;128(Pt 7):1622–1633.
   PubMed Web of Science ®Google Scholar
• Li M, Ma RN, Li LH, et al. Astragaloside IV reduces cerebral edema post-ischemia/reperfusion correlating the suppression of MMP-9 and AQP4. Eur J Pharmacol. 2013 Sep 5;715(1–3):189–195.
   PubMed Web of Science ®Google Scholar
• Rosenberg G, Bornstein N, Diener HC, et al. The membrane-activated chelator stroke intervention (MACSI) trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study. Int J Stroke. 2011 Aug;6(4):362–367.
   PubMed Web of Science ®Google Scholar
• Lees KR, Bornstein N, Diener HC, et al. Results of membrane-activated chelator stroke intervention randomized trial of DP-b99 in acute ischemic stroke. Stroke. 2013 Mar;44(3):580–584.
   PubMed Web of Science ®Google Scholar
• Stokum JA, Gerzanich V, Sheth KN, et al. Emerging pharmacological treatments for cerebral edema: evidence from clinical studies. Annu Rev Pharmacol Toxicol. 2020;60:291–309.
   PubMed Web of Science ®Google Scholar
• Del Bigio MR, Fedoroff S. Swelling of astroglia in vitro and the effect of arginine vasopressin and atrial natriuretic peptide. Acta Neurochir Suppl (Wien). 1990;51:14–16.
   PubMedGoogle Scholar
• Vajda Z, Pedersen M, Dóczi T, et al. Effects of centrally administered arginine vasopressin and atrial natriuretic peptide on the development of brain edema in hyponatremic rats. Neurosurgery. 2001 Sep;49(3):697–704.
   PubMed Web of Science ®Google Scholar
• Kleindienst A, Fazzina G, Dunbar JG, et al. Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. Acta Neurochir Suppl. 2006;96:303–306.
   PubMedGoogle Scholar
• Liu X, Nakayama S, Amiry-Moghaddam M, et al. Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke. Neurocrit Care. 2010 Feb;12(1):124–131.
   PubMed Web of Science ®Google Scholar
• Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005 Aug;25(8):1012–1019.
   PubMed Web of Science ®Google Scholar
• Shuaib A, Xu Wang C, Yang T, et al. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke. 2002 Dec;33(12):3033–3037.
   PubMed Web of Science ®Google Scholar
• Manaenko A, Fathali N, Khatibi NH, et al. Post-treatment with SR49059 improves outcomes following an intracerebral hemorrhagic stroke in mice. Acta Neurochir Suppl. 2011;111:191–196.
   PubMedGoogle Scholar
• Taya K, Gulsen S, Okuno K, et al. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta Neurochir Suppl. 2008;102:425–429.
   PubMedGoogle Scholar
• Molnár AH, Varga C, Berkó A, et al. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia. Acta Neurochir (Wien). 2008 Mar;150(3):265–271.
   PubMed Web of Science ®Google Scholar
• László FA, Varga C, Nakamura S. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage. Eur J Pharmacol. 1999 Jan 8;364(2–3):115–122.
   PubMed Web of Science ®Google Scholar
• Zeynalov E, Jones SM, Elliott JP. Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice. PLoS One. 2017;12(8):e0183985.
   PubMed Web of Science ®Google Scholar
• Dhar R, Murphy-Human T. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury. Neurocrit Care. 2011 Feb;14(1):97–102.
   PubMed Web of Science ®Google Scholar
• Potts MB, DeGiacomo AF, Deragopian L, et al. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion. Neurosurgery. 2011 Aug;69(2):268–273.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Amiry-Moghaddam M, Ottersen OP, et al. Conivaptan, a selective arginine vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of aquaporin-4. Neurocrit Care. 2016 Apr;24(2):273–282.
   PubMed Web of Science ®Google Scholar
• Corry JJ, Asaithambi G, Shaik AM, et al. Conivaptan for the reduction of cerebral edema in intracerebral hemorrhage: a safety and tolerability study. Clin Drug Investig. 2020 May;40(5):503–509. .
   PubMed Web of Science ®Google Scholar
• Tan Q, Li Y, Guo P, et al. Tolvaptan attenuated brain edema in experimental intracerebral hemorrhage. Brain Res. 2019 Jul;15(1715):41–46.
   Web of Science ®Google Scholar
• Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008 Oct;8(10):753–763.
   PubMed Web of Science ®Google Scholar
• Pham TH, Okada T, Matloubian M, et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008 Jan;28(1):122–133.
   PubMed Web of Science ®Google Scholar
• Du J, Zeng C, Li Q, et al. LPS and TNF-α induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells. Pathol Res Pract. 2012 Feb 15;208(2):82–88.
   PubMed Web of Science ®Google Scholar
• Garcia JG, Liu F, Verin AD, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001 Sep;108(5):689–701.
   PubMed Web of Science ®Google Scholar
• Sanchez T, Skoura A, Wu MT, et al. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1312–1318.
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010 Mar-Apr;33(2):91–101.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011 May;69(5):759–777.
   PubMed Web of Science ®Google Scholar
• La Mantia L, Tramacere I, Firwana B, et al. Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2016 Apr;19(4):Cd009371
   Google Scholar
• Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011 Jan;69(1):119–129.
   PubMed Web of Science ®Google Scholar
• Rolland WB, Lekic T, Krafft PR, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013 Mar;241:45–55.
   PubMed Web of Science ®Google Scholar
• Lu L, Barfejani AH, Qin T, et al. Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage. Brain Res. 2014 Mar;25(1555):89–96.
   Web of Science ®Google Scholar
• Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014 Sep;71(9):1092–1101.
   PubMed Web of Science ®Google Scholar
• Woo SK, Kwon MS, Ivanov A, et al. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J Biol Chem. 2013 Feb 1;288(5):3655–3667.
   PubMed Web of Science ®Google Scholar
• Chen M, Simard JM. Cell swelling and a nonselective cation channel regulated by internal Ca2+ and ATP in native reactive astrocytes from adult rat brain. J Neurosci. 2001 Sep 1;21(17):6512–6521.
   PubMed Web of Science ®Google Scholar
• Huang K, Gu Y, Hu Y, et al. Glibenclamide improves survival and neurologic outcome after cardiac arrest in rats. Crit Care Med. 2015 Sep;43(9):e341–9.
   PubMed Web of Science ®Google Scholar
• Huang K, Wang Z, Gu Y, et al. Glibenclamide is comparable to target temperature management in improving survival and neurological outcome after asphyxial cardiac arrest in rats. J Am Heart Assoc. 2016 Jul 13;5(7). DOI:10.1161/JAHA.116.003465.
   Web of Science ®Google Scholar
• Huang K, Wang Z, Gu Y, et al. Glibenclamide prevents water diffusion abnormality in the brain after cardiac arrest in rats. Neurocrit Care. 2018 Aug;29(1):128–135.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Taguchi N, Isaka Y, et al. Glibenclamide and therapeutic hypothermia have comparable effect on attenuating global cerebral edema following experimental cardiac arrest. Neurocrit Care. 2018 Aug;29(1):119–127.
   PubMed Web of Science ®Google Scholar
• Simard JM, Yurovsky V, Tsymbalyuk N, et al. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009 Feb;40(2):604–609.
   PubMed Web of Science ®Google Scholar
• Simard JM, Tsymbalyuk N, Tsymbalyuk O, et al. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke. 2010 Mar;41(3):531–537.
   PubMed Web of Science ®Google Scholar
• Simard JM, Woo SK, Tsymbalyuk N, et al. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl Stroke Res. 2012 Jun;3(2):286–295.
   PubMed Web of Science ®Google Scholar
• Wali B, Ishrat T, Atif F, et al. Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res Treat. 2012;2012:460909.
   PubMedGoogle Scholar
• Simard JM, Tsymbalyuk O, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest. 2007 Aug;117(8):2105–2113
   PubMed Web of Science ®Google Scholar
• Simard JM, Woo SK, Norenberg MD, et al. Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Sci Transl Med. 2010 Apr 21;2(28):28ra29.
   PubMed Web of Science ®Google Scholar
• Simard JM, Popovich PG, Tsymbalyuk O, et al. Spinal cord injury with unilateral versus bilateral primary hemorrhage–effects of glibenclamide. Exp Neurol. 2012 Feb;233(2):829–835. .
   PubMed Web of Science ®Google Scholar
• Hosier H, Peterson D, Tsymbalyuk O, et al. A direct comparison of three clinically relevant treatments in a rat model of cervical spinal cord injury. J Neurotrauma. 2015 Nov 1;32(21):1633–1644.
   PubMed Web of Science ®Google Scholar
• Simard JM, Kilbourne M, Tsymbalyuk O, et al. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J Neurotrauma. 2009 Dec;26(12):2257–2267.
   PubMed Web of Science ®Google Scholar
• Patel AD, Gerzanich V, Geng Z, et al. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol. 2010 Dec;69(12):1177–1190.
   PubMed Web of Science ®Google Scholar
• Zweckberger K, Hackenberg K, Jung CS, et al. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience. 2014 Jul;11(272):199–206.
   Web of Science ®Google Scholar
• Xu ZM, Yuan F, Liu YL, et al. Glibenclamide attenuates blood-brain barrier disruption in adult mice after traumatic brain injury. J Neurotrauma. 2017 Feb 15;34(4):925–933.
   PubMed Web of Science ®Google Scholar
• Jha RM, Molyneaux BJ, Jackson TC, et al. Glibenclamide produces region-dependent effects on cerebral edema in a combined injury model of traumatic brain injury and hemorrhagic shock in mice. J Neurotrauma. 2018 Sep 1;35(17):2125–2135.
   PubMed Web of Science ®Google Scholar
• Kochanek PM, Bramlett HM, Dixon CE, et al. Operation brain trauma therapy: 2016 update. Mil Med. 2018 Mar 1;183(suppl_1):303–312.
   PubMed Web of Science ®Google Scholar
• Simard JM, Geng Z, Woo SK, et al. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2009 Feb;29(2):317–330.
   PubMed Web of Science ®Google Scholar
• Tosun C, Kurland DB, Mehta R, et al. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke. 2013 Dec;44(12):3522–3528. .
   PubMed Web of Science ®Google Scholar
• Jiang B, Li L, Chen Q, et al. Role of glibenclamide in brain injury after intracerebral hemorrhage. Transl Stroke Res. 2017 Apr;8(2):183–193.
   PubMed Web of Science ®Google Scholar
• Simard PF, Tosun C, Melnichenko L, et al. Inflammation of the choroid plexus and ependymal layer of the ventricle following intraventricular hemorrhage. Transl Stroke Res. 2011 Jun;2(2):227–231.
   PubMed Web of Science ®Google Scholar
• Jayakumar AR, Valdes V, Tong XY, et al. Sulfonylurea receptor 1 contributes to the astrocyte swelling and brain edema in acute liver failure. Transl Stroke Res. 2014 Feb;5(1):28–37.
   PubMed Web of Science ®Google Scholar
• Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2012 Dec;18(12):1805–1811.
   PubMed Web of Science ®Google Scholar
• Makar TK, Gerzanich V, Nimmagadda VK, et al. Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2015 Nov 18;12:210.
   PubMed Web of Science ®Google Scholar
• Gerzanich V, Makar TK, Guda PR, et al. Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis. J Neuroinflammation. 2017 Sep 2;14(1):177.
   PubMed Web of Science ®Google Scholar
• Thulé PM, Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep. 2014 Apr;14(4):473.
   PubMed Web of Science ®Google Scholar
• Simard JM, Geng Z, Silver FL, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci. 2012 Sep;1268:95–107.
   PubMed Web of Science ®Google Scholar
• Wilkinson CM, Brar PS, Balay CJ, et al. Glibenclamide, a Sur1-Trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage. PLoS One. 2019;14(5):e0215952.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Kimberly WT, Elm JJ, et al. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014 Aug;21(1):43–51.
   PubMed Web of Science ®Google Scholar
• Kimberly WT, Bevers MB, von Kummer R, et al. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018 Dec 4;91(23):e2163–e2169.
   PubMed Web of Science ®Google Scholar
• King ZA, Sheth KN, Kimberly WT, et al. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date. Drug Des Devel Ther. 2018;12:2539–2552.
   PubMed Web of Science ®Google Scholar